Under the deal, the companies would offer the lowest dose of their respective obesity drugs at $149 per month, the report said, citing sources familiar with the matter.

A Delaware judge said on Tuesday she did not see in a preliminary evaluation the need to involve the court in the bidding war for Metsera between Pfizer and Novo Nordisk, but did schedule another hear...

The higher offers signal just how far the two pharma giants will go to secure next-generation weight-loss drugs.